| 高 翔,周 平,谢志皓,等.神经胶质瘤预后分子标志物的研究进展[J].肿瘤学杂志,2024,30(11):946-955. |
| 神经胶质瘤预后分子标志物的研究进展 |
| Research Progress on Molecular Markers for Prognosis of Glioma Patient |
| 投稿时间：2024-06-27 |
| DOI：10.11735/j.issn.1671-170X.2024.11.B009 |
|
 |
| 中文关键词: 神经胶质瘤 分子标志物 预后评估 基因组学 转录组学 |
| 英文关键词:gliomas molecular marker prognostic evaluation genomics transcriptomics |
| 基金项目:国家自然科学基金地区科学基金项目（82260474） |
|
| 摘要点击次数: 63 |
| 全文下载次数: 8 |
| 中文摘要: |
| 摘 要： 神经胶质瘤是成人中枢神经系统的常见肿瘤，其恶性亚型预后较差，亟需寻找有效预后分子标志物。全文基于基因组学、转录组学和代谢组学技术，系统总结了神经胶质瘤的代表性预后分子标志物。在基因组学方面，1p/19q缺失提示预后良好，而组蛋白H3.3A和端粒酶逆转录酶启动子突变是神经胶质瘤不良预后因素。此外，异柠檬酸脱氢酶1突变与胶质母细胞瘤不良预后相关。转录组学方面，微小RNA21高表达的神经胶质瘤患者生存期较短；而代谢组学标志物中，四跨膜蛋白家族7高表达患者生存率较高，逐渐成为新的临床预后评估标志物。 |
| 英文摘要: |
| Abstract： Glioma is a category of tumors in the adult central nervous system， its malignant subtypes are frequently associated with poor prognosis. To improve clinical outcomes，it is necessary to find more effective prognostic molecular markers for prognosis of gliomas. Recent genomic studies have shown that the co-deletion of 1p/19q is indicative of a more favorable prognosis， whereas mutations in histone H3.3A and the telomerase reverse transcriptase promoter are closely associated with poorer outcomes； isocitrate dehydro genase 1 mutations， in particular， are strongly predictive of adverse prognoses in glioblastoma. Transcriptomic studies have revealed that elevated microRNA-21 expression is linked to reduced survival in glioma patients. Metabolomics studies have found that higher expression of tetraspainis7 is correlated with improved survival， positioning it as an emerging prognostic marker in in clinical practice. This paper reviews recent advances on novel molecular markers for prognosis of glioma patients in identified by genomics， transcriptomics and metabolomics studies to provide insights on clinical prognostic evaluation as well more precise therapeutic approaches of gliomas. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |